The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators" through the National Cancer Institute (NCI). This initiative aims to encourage research focused on the discovery and development of small molecules that can probe cancer biology and contribute to drug development. Eligible applicants include various educational institutions, non-profit organizations, and government entities, with funding up to three years, though application budgets are flexible. The research phases covered are: developing primary screen assays, implementing primary screens, and validating hits through precise assays. The use of advanced screening technologies, including virtual screening and collaborative efforts with experts, is encouraged. Key dates include a posting date of November 6, 2024, with the application deadline beginning January 5, 2025, and an expiration date set for September 8, 2026. Applicants must comply with detailed submission guidelines, including the use of updated application forms. Overall, this funding opportunity aims to enhance the understanding of cancer biology and develop new therapeutic strategies while adhering to strict compliance and scientific merit review standards.